Insider account of UCB’s $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy — and $120M windfall for execs

When the Ra Pharma team hit San Francisco for JP Morgan last January, they were on a mission: Find a deal for their C5 inhibitor zilucoplan at the threshold of late-stage development for myasthenia gravis. And by the time they were done negotiating nearer the end of the year, the…

Click to view original post